Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey Langer

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experienceJared Weiss, Beth Eaby, James Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerHossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, et al.
Clinical Lung Cancer|February 20, 2008
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancerHeather Wakelee, Corey Langer, Everett Vokes, et al.
Cancer|May 20, 2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinomaJared M Weiss, Stephen Bagley, Wei-Ting Hwang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancerSteven J Feigenberg, Alexandra L Hanlon, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2008
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801Linda Sarna, Suzanne Swann, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2007
Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysisLoren K Mell, Renuka Malik, Ritsuko Komaki, et al.
The Journal of Community and Supportive Oncology|June 28, 2014
Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative studyJoanne Buzaglo, Christopher Gayer, Rajiv Mallick, et al.
Annals of the American Thoracic Society|September 28, 2016
How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision MakingMarilyn M Schapira, Charu Aggarwal, Scott Akers, et al.
Oncotarget|October 17, 2015
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapyAnna K Brady, Jonathan D McNeill, Brendan Judy, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experienceJared Weiss, Beth Eaby, James Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerHossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, et al.
Clinical Lung Cancer|February 20, 2008
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancerHeather Wakelee, Corey Langer, Everett Vokes, et al.
Cancer|May 20, 2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinomaJared M Weiss, Stephen Bagley, Wei-Ting Hwang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancerSteven J Feigenberg, Alexandra L Hanlon, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2008
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801Linda Sarna, Suzanne Swann, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2007
Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysisLoren K Mell, Renuka Malik, Ritsuko Komaki, et al.
The Journal of Community and Supportive Oncology|June 28, 2014
Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative studyJoanne Buzaglo, Christopher Gayer, Rajiv Mallick, et al.
Annals of the American Thoracic Society|September 28, 2016
How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision MakingMarilyn M Schapira, Charu Aggarwal, Scott Akers, et al.
Oncotarget|October 17, 2015
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapyAnna K Brady, Jonathan D McNeill, Brendan Judy, et al.
Pageof 11